Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8WVM0

UPID:
TFB1M_HUMAN

ALTERNATIVE NAMES:
Mitochondrial 12S rRNA dimethylase 1; Mitochondrial transcription factor B1; S-adenosylmethionine-6-N', N'-adenosyl(rRNA) dimethyltransferase 1

ALTERNATIVE UPACC:
Q8WVM0; Q05DR0; Q9Y384

BACKGROUND:
The enzyme Dimethyladenosine transferase 1, mitochondrial, known for its specific dimethylation of mitochondrial 12S rRNA, is essential for mitochondrial DNA transcription. It operates through interactions with POLRMT and TFAM, enhancing transcription independently of its methyltransferase function. This enzyme's alternative names include Mitochondrial transcription factor B1 and S-adenosylmethionine-6-N', N'-adenosyl(rRNA) dimethyltransferase 1.

THERAPEUTIC SIGNIFICANCE:
The exploration of Dimethyladenosine transferase 1, mitochondrial's function offers a promising avenue for developing novel therapeutic approaches. Given its pivotal role in mitochondrial DNA transcription and rRNA processing, targeting this enzyme could lead to breakthroughs in treating mitochondrial-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.